Related Experiment Video
Updated: Jun 28, 2026

A Plate-Based Assay for the Measurement of Endogenous Monoamine Release in Acute Brain Slices
Published on: August 11, 2021
Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants
Stephen M Stahl1, Angela Felker
1Department of Psychiatry, University of California-San Diego, La Jolla, CA, USA.
Abstract:
Monoamine oxidase inhibitors (MAOIs) currently have a "bad rap" and are thus infrequently used in psychopharmacology, even by experienced clinicians. Misinformation about the dietary and drug interactions of MAOIs is widespread, whereas pragmatic tips for utilizing MAOIs to minimize risks and to maximize therapeutic actions are largely lacking in the contemporary literature. While clearly not first-line treatments, MAOIs, in the hands of experienced and well-informed clinicians, can be a powerful therapeutic intervention for patients with depression, panic disorder, and other anxiety disorders who have failed first-line treatments. This article focuses on the pharmacologic mechanisms of MAOIs, since an understanding of these mechanisms may provide a rationale to empower experts to expand their use of these agents. Discussed here are not only the mechanisms of therapeutic action of MAOIs, but also the mechanisms explaining their side effects, including hypertensive interactions with dietary tyramine (so-called "cheese reactions") and drug interactions that can lead to hypertensive reactions with some drugs and serotonin toxicities with others. This article also provides practical tips on how to use MAOIs, including debunking certain myths and giving specific guidance about which foods and drugs to avoid. Those with no previous interest in MAOIs may discover in this article a new "secret weapon" to add to their therapeutic armamentarium for patients who fail to respond to the better-known agents.
Insights
Monoamine oxidase inhibitors (MAOIs) are powerful antidepressants for treatment-resistant patients. Understanding their mechanisms and practical use can overcome misinformation and expand their clinical application.
Area of Science:
- Psychopharmacology
- Neuroscience
- Medical Chemistry
Background:
- Monoamine oxidase inhibitors (MAOIs) are underutilized in clinical practice due to widespread misinformation.
- Lack of practical guidance hinders the use of MAOIs, despite their therapeutic potential.
Purpose of the Study:
- To elucidate the pharmacologic mechanisms of MAOIs for therapeutic and adverse effects.
- To provide practical strategies for safe and effective MAOI utilization.
- To debunk myths surrounding MAOI use and offer guidance on dietary and drug interactions.
Main Methods:
- Review of pharmacologic mechanisms of MAOIs.
- Analysis of mechanisms underlying therapeutic actions and side effects (hypertensive and serotonin toxicities).
- Compilation of practical tips for MAOI administration, including food and drug avoidance.
Main Results:
- Understanding MAOI mechanisms can empower clinicians to use them effectively.
- MAOIs can be a potent intervention for treatment-resistant depression and anxiety disorders.
- Specific guidance is provided to mitigate risks associated with MAOIs.
Conclusions:
- MAOIs, when used by informed clinicians, can be a valuable tool for refractory psychiatric conditions.
- Dispelling myths and providing practical advice can increase the appropriate use of MAOIs.
- This article aims to reintroduce MAOIs as a viable option in the psychopharmacological armamentarium.
Related Concept Videos
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drug Therapy
Antianxiety Medications
Drugs Affecting Neurotransmitter Release or Uptake
